Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis

被引：0
|
作者：
Vermeire, S. [1 ,2 ]
Danese, S. [3 ,4 ]
Zhou, W. [5 ]
Klaff, J. [5 ]
Ilo, D. [5 ]
Yao, X. [6 ]
Levy, G. [7 ]
Higgins, P. D. R. [8 ]
Loftus-, E. V., Jr. [9 ]
Panaccione, R. [10 ]
机构：
[1] Univ Hosp Leuven, Leuven, Belgium
[2] Katholieke Univ Leuven, Gastroenterol & Hepatol, Leuven, Belgium
[3] IRCCS Osped San Raffaele, Milan, Italy
[4] Univ Vita Salute San Raffaele, Gastroenterol & Endoscopy, Milan, Italy
[5] AbbVie Inc, Res & Dev, N Chicago, IL USA
[6] AbbVie Inc, Data & Stat Sci, N Chicago, IL USA
[7] AbbVie Inc, Pharmacovigilance & Patient Safety, N Chicago, IL USA
[8] Univ Michigan, Dept Med, Div Gastroenterol, Ann Arbor, MI USA
[9] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN USA
[10] Univ Calgary, Inflammatory Bowel Dis Unit, Div Gastroenterol & Hepatol, Calgary, AB, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP41
引用
收藏
页码：I090 / I091
页数：3
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF EXTENDED INDUCTION TREATMENT WITH UPADACITINIB 45 MG ONCE DAILY FOLLOWED BY MAINTENANCE UPADACITINIB 15 OR 30 MG ONCE DAILY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Vermeire, Severine
    Danese, Silvio
    Zhou, Wen
    Klaff, Justin
    Ilo, Dapo
    Yao, Xuan
    Levy, Gweneth
    Higgins, Peter D.
    Loftus, Edward V.
    Panaccione, Remo
    GASTROENTEROLOGY, 2022, 162 (07) : S227 - S228
  • [2] Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis
    Panaccione, Remo
    Danese, Silvio
    Zhou, Wen
    Klaff, Justin
    Ilo, Dapo
    Yao, Xuan
    Levy, Gweneth
    Higgins, Peter D. R.
    Loftus Jr, Edward V.
    Chen, Su
    Gonzalez, Yuri Sanchez
    Leonard, Carolyn
    Hebuterne, Xavier
    Lindsay, James O.
    Cao, Qian
    Nakase, Hiroshi
    Colombel, Jean-Frederic
    Vermeire, Severine
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (03) : 393 - 408
  • [3] Benefit-Risk Assessment of Upadacitinib Treatment in Patients With Moderately to Severely Active Ulcerative Colitis
    Panaccione, Remo
    Blumenstein, Irina
    Irving, Peter
    Vladea, Ramona
    Ilo, Dapo
    Zhou, Wen
    Levy, Gweneth
    Yao, Xuan
    Dotan, Iris
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S553 - S554
  • [4] Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis
    Dulai, P.
    Sands, B. E.
    Danese, S.
    Peyrin-Biroulet, L.
    Dubinsky, M.
    Tilg, H.
    Siegmund, B.
    Sloan, S.
    Ploncard, P.
    Rabbat, C.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1778 - I1778
  • [5] Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis
    Babu, P. Ravindra
    Pravin, A. J. S.
    Deshmukh, Gaurav
    Dhoot, Dhiraj
    Samant, Aniket
    Kotak, Bhavesh
    INDIAN JOURNAL OF DERMATOLOGY, 2017, 62 (04) : 395 - 399
  • [6] Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
    Reinisch, W.
    Panaccione, R.
    Duijvestein, M.
    Santos, D. Ceballos
    Melmed, G. Y.
    Xuan, S.
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 672 - 672
  • [7] Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison
    Reinisch, W.
    Tran, J.
    Patel, K.
    Borruel, N.
    Melmed, G. Y.
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 785 - 786
  • [8] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
    Vermeire, S.
    Danese, S.
    Zhou, W.
    Pangan, A.
    Greenbloom, S.
    D'Haens, G.
    Panes, J.
    Juillerat, P.
    Lindsay, J. O.
    Loftus, E. V., Jr.
    Sandborn, W. J.
    Reinisch, W.
    Gonzalez, Y. Sanchez
    Huang, B.
    Xie, W.
    Liu, J.
    Weinreich, M. A.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022
  • [9] Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis
    Blumenstein, I.
    Xuan, S.
    Panaccione, R.
    Baert, F.
    Barreiro-de Acosta, M.
    Ye, B. D.
    Klaff, J.
    Vladea, R.
    Levy, G.
    Holweg, C. T. J.
    Gonzalez, Y. Sanchez
    Dubinsky, M. C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I333 - I334
  • [10] Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
    Danese, S.
    Vermeire, S.
    Zhou, W.
    Pangan, A.
    Siffledeen, J.
    Hebuterne, X.
    Nakase, H.
    Higgins, P.
    Chen, M. H.
    Sanchez-Gonzalez, Y.
    Huang, B.
    Xie, W.
    Liu, J.
    Weinreich, M.
    Pannaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S022 - S024
12345